LONDON - Oxford Biomedica plc said the first patient is within days of being treated with ProSavin, its gene therapy treatment for Parkinson's disease. The neurosurgery required to administer it has been booked, but the company has agreed with the Henri Mondor Hospital in Paris where the trial is taking place not to disclose the actual date. (BioWorld International) Read More
